These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29136401)

  • 1. Drugs for Parkinson's disease.
    Med Lett Drugs Ther; 2017 Nov; 59(1534):187-194. PubMed ID: 29136401
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison table: drugs for Parkinson's disease.
    Med Lett Drugs Ther; 2017 Nov; 59(1534):e194-e196. PubMed ID: 29136402
    [No Abstract]   [Full Text] [Related]  

  • 3. Safinamide (Xadago) for Parkinson's disease.
    Med Lett Drugs Ther; 2017 Sep; 59(1529):151-153. PubMed ID: 28880847
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of duloxetine on motor and mood symptoms in Parkinson's disease: An open-label clinical experience.
    Nishijima H; Ueno T; Kon T; Haga R; Funamizu Y; Arai A; Suzuki C; Nunomura JI; Baba M; Tomiyama M
    J Neurol Sci; 2017 Apr; 375():186-189. PubMed ID: 28320128
    [No Abstract]   [Full Text] [Related]  

  • 5. Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
    Med Lett Drugs Ther; 2015 Aug; 57(1474):112. PubMed ID: 26218794
    [No Abstract]   [Full Text] [Related]  

  • 6. Parkinson's disease: initial treatment of motor disorders.
    Prescrire Int; 2015 Sep; 24(163):215-7. PubMed ID: 26417634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa and the progression of Parkinson's disease.
    Walton-Hadlock JL
    N Engl J Med; 2005 Mar; 352(13):1386; author reply 1386. PubMed ID: 15800240
    [No Abstract]   [Full Text] [Related]  

  • 8. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    Neurology; 1998 Feb; 50(2):573-4. PubMed ID: 9484410
    [No Abstract]   [Full Text] [Related]  

  • 9. Gabapentin and motor fluctuations in Parkinson's disease.
    Chaná P; de Marinis A; Barrientos N
    Mov Disord; 1997 Jul; 12(4):608. PubMed ID: 9251083
    [No Abstract]   [Full Text] [Related]  

  • 10. Future delivery systems for apomorphine in patients with Parkinson's disease.
    van Laar T; Van der Geest R; Danhof M
    Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
    [No Abstract]   [Full Text] [Related]  

  • 11. Drugs for Parkinson's disease.
    Lees AJ
    J Neurol Neurosurg Psychiatry; 2002 Dec; 73(6):607-10. PubMed ID: 12438454
    [No Abstract]   [Full Text] [Related]  

  • 12. Future strategies for the treatment of Parkinson's disease.
    Fahn S
    Adv Neurol; 1993; 60():636-40. PubMed ID: 8420202
    [No Abstract]   [Full Text] [Related]  

  • 13. Parkinson's disease. An overview of treatments and research.
    Tuite PJ
    Minn Med; 2001 May; 84(5):42-7. PubMed ID: 11398632
    [No Abstract]   [Full Text] [Related]  

  • 14. Getting a grasp on research: does treatment taint testing of parkinsonian patients?
    Gordon AM; Reilmann R
    Brain; 1999 Aug; 122 ( Pt 8)():1597-8. PubMed ID: 10430842
    [No Abstract]   [Full Text] [Related]  

  • 15. Parkinson's disease.
    Clarke C; Moore AP
    Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
    [No Abstract]   [Full Text] [Related]  

  • 16. Off and on state assessment of swallowing function in Parkinson's disease.
    Warnecke T; Hamacher C; Oelenberg S; Dziewas R
    Parkinsonism Relat Disord; 2014 Sep; 20(9):1033-4. PubMed ID: 24997546
    [No Abstract]   [Full Text] [Related]  

  • 17. l-dopa-induced off: Functional overlay in Parkinson disease.
    Erro R; Bozzetti S; Goffi F; Mariotto S; Tinazzi M
    J Neurol Sci; 2016 Jun; 365():1-2. PubMed ID: 27206863
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of Parkinson's disease.
    Calne DB
    N Engl J Med; 1993 Sep; 329(14):1021-7. PubMed ID: 8366903
    [No Abstract]   [Full Text] [Related]  

  • 19. Lingual protrusion dystonia: Manifestation during "on" periods in Parkinson's disease.
    Maiola R; Ramirez Gómez CC; Micheli F
    J Neurol Sci; 2016 Nov; 370():256-257. PubMed ID: 27772770
    [No Abstract]   [Full Text] [Related]  

  • 20. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.